CTOs on the Move

Advanced Cardiac Therapeutics Inc

www.actmed.net

 
Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.actmed.net
  • 1278 Glenneyre Suite 139
    Laguna Beach, CA USA 92651
  • Phone: 949.500.0192

Executives

Name Title Contact Details

Funding

Advanced Cardiac Therapeutics Inc raised $45M on 05/02/2017

Similar Companies

Oklahoma Occupational Therapy Association (OOTA)

Oklahoma Occupational Therapy Association (OOTA) is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cadent

Cadent is a Carlstadt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arizant Healthcare, a 3M company

Arizant Inc.'s main subsidiary, Arizant Healthcare Inc., pioneered the concept of forced-air patient warming with the introduction of Bair Hugger therapy in 1987. Fueled by the success of Bair Hugger therapy, the company has continuously displayed

Sightech Vision Systems

Sightech Vision Systems is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elucid

Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe